Megan Baumgart

408 total citations
17 papers, 156 citations indexed

About

Megan Baumgart is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Megan Baumgart has authored 17 papers receiving a total of 156 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 3 papers in Molecular Biology. Recurrent topics in Megan Baumgart's work include Lung Cancer Treatments and Mutations (5 papers), HER2/EGFR in Cancer Research (3 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Megan Baumgart is often cited by papers focused on Lung Cancer Treatments and Mutations (5 papers), HER2/EGFR in Cancer Research (3 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Megan Baumgart collaborates with scholars based in United States, Canada and Germany. Megan Baumgart's co-authors include Mary W. Redman, Roy S. Herbst, Karen Kelly, Scott Gettinger, David R. Gandara, Leora Horn, Jean E. Patterson, Kathleen A. Merkler, Mary Ann Melnick and Mitchell A. deLong and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Biochemistry.

In The Last Decade

Megan Baumgart

17 papers receiving 155 citations

Peers

Countries citing papers authored by Megan Baumgart

Since Specialization

Citations

This map shows the geographic impact of Megan Baumgart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Megan Baumgart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Megan Baumgart more than expected).

Fields of papers citing papers by Megan Baumgart

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Megan Baumgart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Megan Baumgart. The network helps show where Megan Baumgart may publish in the future.

Co-authorship network of co-authors of Megan Baumgart

This figure shows the co-authorship network connecting the top 25 collaborators of Megan Baumgart. A scholar is included among the top collaborators of Megan Baumgart based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Megan Baumgart. Megan Baumgart is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	1309P A genomic scar based signature (HRDsig) and biallelic BRCA alterations identify a homologous recombination deficiency (HRD) phenotype of non-small cell lung cancer (NSCLC) potentially actionable to the PARP inhibitor rucaparib: Post-hoc analysis of lung-MAP substudy S1900A 2024 ·Annals of Oncology ·Jonathan W. Riess, Jieling Miao, Paul Wheatley‐Price, Karen L. Reckamp, David Kozono, (unknown), Martin J. Edelman, (unknown), (unknown), Linda Corum, Ashok Gowda, Gordan Srkalović, Raymond U. Osarogiagbon, Megan Baumgart, (unknown), (unknown), Hossein Borghaei, Jhanelle E. Gray, Roy S. Herbst, Karen Kelly	1
2	Patient-reported impact of symptoms in lung cancer (PRISM-LC) 2023 ·Translational Lung Cancer Research ·(unknown), (unknown), (unknown), (unknown), (unknown), Nuran Dilek, (unknown), Megan Baumgart, Deborah Mulford, Ronald J. Maggiore, (unknown), Jennifer C. King, Jacinta Wiens, Chad Heatwole	4
3	Phase 1/2 study of pepinemab, an inhibitor of semaphorin 4D, in combination with pembrolizumab as first-line treatment of recurrent or metastatic head and neck cancer (KEYNOTE-B84). 2022 ·Journal of Clinical Oncology ·Terrence L. Fisher, Elizabeth E. Evans, Crystal Mallow, (unknown), (unknown), Ernest Smith, John E. Leonard, Marya Chaney, J. Thaddeus Beck, Steven Hager, Tarek Mekhail, Nagashree Seetharamu, Megan Baumgart, Nabil F. Saba, Conor Steuer, Douglas Adkins, Barbara Burtness, Maurice Zauderer	1
4	Next generation sequencing of sarcomas: Response to crizotinib in two cases with MET amplification. 2021 ·Journal of Clinical Oncology ·Adrienne I. Victor, (unknown), Megan Baumgart, Gaurav Goyal, Deepak M. Sahasrabudhe	2
5	Rapid-onset and fatal pneumonitis from trametinib treatment of non-small cell lung cancer: A case report 2021 ·Seyed Mohammad Abedi, (unknown), Yuhchyau Chen, Megan Baumgart, Arpan Patel	1
6	Safety and pharmacokinetics of docetaxel in combination with pegvorhyaluronidase alfa in patients with non‐small cell lung cancer 2021 ·Clinical and Translational Science ·Thomas C. Heineman, Megan Baumgart, (unknown), N. Gabrail, Scott A. Van Wart, Donald E. Mager, Daniel C. Maneval, (unknown), Rose E. Sekulovich	7
7	A phase II study of rucaparib in patients with high genomic LOH and/or BRCA 1/2 mutated stage IV non-small cell lung cancer (Lung-MAP Sub-Study, S1900A). 2021 ·Journal of Clinical Oncology ·Jonathan W. Riess, Mary W. Redman, Paul Wheatley‐Price, Bryan A. Faller, Liza C. Villaruz, (unknown), Aruna Gowda, Gordan Srkalović, Raymond U. Osarogiagbon, Megan Baumgart, (unknown), Katherine Minichiello, David R. Gandara, Roy S. Herbst, Karen Kelly	8
8	Portable medical orders and end-of-life measures in acute myeloid leukemia and myelodysplastic syndromes 2021 ·Blood Advances ·(unknown), Andrea Baran, Jane L. Liesveld, (unknown), (unknown), Kristen M. O’Dwyer, Omar S. Aljitawi, Megan Baumgart, Eric M. Snyder, Benzi M. Kluger, Kah Poh Loh, Jason H. Mendler	5
9	Risk of brain metastases in T1–3N0 NSCLC: a population-based analysis 2020 ·PubMed ·Michael T. Milano, James E. Bates, (unknown), Haoming Qiu, Sara Hardy, (unknown), Megan Baumgart, Ronald J. Maggiore, Deborah Mulford, Kenneth Y. Usuki	7
10	Early Completion of Medical Orders for Life-Sustaining Treatment (MOLST) and Hospice Enrollment Are Associated with Improved End of Life (EOL) Quality Metrics in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) 2020 ·Blood ·(unknown), Kah Poh Loh, Andrea Baran, Jane L. Liesveld, Michael W. Becker, Kristen M. O’Dwyer, (unknown), Omar S. Aljitawi, Megan Baumgart, Eric M. Snyder, Benzi M. Kluger, Jason H. Mendler	1
11	Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non–Small-Cell Lung Cancer: Final Results From SWOG S1403 2020 ·Journal of Clinical Oncology ·Sarah B. Goldberg, Mary W. Redman, Rogério Lilenbaum, Katerina Politi, Thomas E. Stinchcombe, Leora Horn, (unknown), Sandeep H. Mashru, Scott Gettinger, Mary Ann Melnick, Roy S. Herbst, Megan Baumgart, Jieling Miao, James Moon, Karen Kelly, David R. Gandara	52
12	Interim results from a phase Ib/II study of pepinemab in combination with avelumab in advanced NSCLC patients following progression on prior systemic and/or anti-PDx therapies. 2020 ·Journal of Clinical Oncology ·Michael Shafique, Terrence L. Fisher, Elizabeth E. Evans, John E. Leonard, (unknown), Crystal Mallow, Ernest Smith, Andreas Schröder, Kevin M. Chin, J. Thaddeus Beck, Megan Baumgart, Ramaswamy Govindan, Nashat Gabrail, Rachel E. Sanborn, Alexander I. Spira, Nagashree Seetharamu, Yanyan Lou, Aaron S. Mansfield, Jonathan W. Goldman, Maurice Zauderer	2
13	Interim subgroup analysis for response by PD-L1 status of CLASSICAL-Lung, a phase Ib/II study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC. 2020 ·Journal of Clinical Oncology ·Michael Shafique, Terrence L. Fisher, Elizabeth E. Evans, John E. Leonard, (unknown), Crystal Mallow, Ernest Smith, Andreas Schröder, Kevin M. Chin, J. Thaddeus Beck, Megan Baumgart, Ramaswamy Govindan, Nashat Gabrail, Rachel E. Sanborn, Alexander I. Spira, Nagashree Seetharamu, Yanyan Lou, Aaron S. Mansfield, Jonathan W. Goldman, Maurice Zauderer	1
14	Preliminary results from CLASSICAL-Lung, a phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC. 2019 ·Journal of Clinical Oncology ·Michael Shafique, Terrence L. Fisher, Elizabeth E. Evans, John E. Leonard, (unknown), Crystal Mallow, Ernest Smith, Maurice Zauderer, Andreas Schröder, Kevin M. Chin, J. Thaddeus Beck, Megan Baumgart, Ramaswamy Govindan, Rachel E. Sanborn, Jonathan W. Goldman	2
15	The use of biomarkers in the treatment of non-small cell lung cancer 2016 ·Expert Review of Precision Medicine and Drug Development ·Megan Baumgart, Kishan J. Pandya	2
16	Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin–bound paclitaxel in patients with advanced solid tumors 2015 ·Cancer ·Maysa Abu‐Khalaf, Megan Baumgart, Scott Gettinger, (unknown), David Tuck, Shihe Hou, Nianhang Chen, Catherine Sullivan, Kimberly Lezon-Geyda, Daniel Zelterman, Christos Hatzis, Hari A. Deshpande, Michael P. DiGiovanna, Masoud Azodi, Peter E. Schwartz, Lyndsay N. Harris	11
17	N-Acylglycine Amidation: Implications for the Biosynthesis of Fatty Acid Primary Amides 1999 ·Biochemistry ·(unknown), (unknown), (unknown), (unknown), Megan Baumgart, Dale L. Boger, (unknown), Mitchell A. deLong, (unknown), (unknown), (unknown), Kathleen A. Merkler, Jean E. Patterson, (unknown), John C. Vederas, David J. Merkler	49

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact